No phaseRecruiting

C2001P-CS3: Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIV

C2001P-CS3 CASCADE: A Feasibility Study of HPV Screening and Management Strategies Utilizing Extended Molecular HPV DNA Genotyping and HPV Viral Load in Women Living With HIV

Sponsor
University of California, San Diego (Academic or other)
Enrollment
750 planned
Conditions
Human Papillomavirus (HPV); HPV Associated Cancers; Cervical Cancer; Human Immunodeficiency Virus (HIV); Cervical Intraepithelial Neoplasia (CIN)
Interventions
HPV DNA Testing (Abbott Alinity m HPV Assay); Visual Inspection with Acetic Acid; Cervical Histology (Biopsy Procedures); Cervical Treatment (Thermal Ablation or LEEP/LLETZ)
Ages
adults, older adults
Registry
NCT07576842

Full record on ClinicalTrials.gov

From the registry

The overall goal of this study is to inform the design and establish feasibility for a future clinical trial to determine the optimal management of women living with HIV (WLWH) with high-risk human papillomavirus (hrHPV) detected on HPV-based cervical cancer screening. WLWH have a higher diversity of anogenital HPV types causing cervical high-grade squamous intraepithelial lesions (hHSIL) and invasive cancer compared to women without HIV. While there is consensus that women testing positive for HPV 16 and/or 18 should be immediately managed and treated, optimal management strategies for women with other hrHPV types (non-16/18) are not well defined. This prospective cohort study will enroll WLWH undergoing cervical cancer screening using primary HPV testing. Women will self-collect vaginal specimens for hrHPV testing using the Abbott Alinity m HPV assay, which provides extended HPV genotyping and a proxy for HPV viral load based on cycle threshold (CT) values. Women with hrHPV detected will return for further evaluation and treatment as indicated. A subset of women will return at…

Primary outcomes

  • Proportion of Potentially Eligible Participants Providing Informed Consent
  • Time to Clinic Receipt of HPV Test Results
  • Percentage of Participants Receiving HPV Test Results
  • Proportion of Participants Returning for Baseline Evaluation

History

  1. Study completion expected

  2. Primary completion expected

  3. Last registry update

  4. Started

  5. Registered